Palvella Therapeutics appoints John Doux, M.D. to Board of Directors

PALVELLA THERAPEUTICS, INC.

Board increased to 7 members; Dr. Doux appointed as Class III director with term expiring at 2026 Annual Meeting.
Dr. Doux is a board-certified dermatologist and analyst at Palo Alto Investors LP since 2004.
Granted option to purchase 6,000 shares vesting in equal monthly installments over 36 months.
Previously served on Palvella's board before reverse merger (2019-2022).
Board determined Dr. Doux independent under Nasdaq listing rules.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.